Govt places orders for 14.5 million doses of Covid-19 vaccines

The orders were placed with Serum Institute of India and Bharat Biotech

coronavirus vaccine
A health worker shows COVID 19 vaccine Covaxin at R. G. Kar Medical College and hospital during COVID 19 vaccine run, in Kolkata
Press Trust of India New Delhi
1 min read Last Updated : Feb 09 2021 | 7:11 PM IST

The government has placed orders for 1 crore (10 million) additional doses of Covishield from Serum Institute of India and 45 lakh (4.5 million) more doses of Covaxin from Bharat Biotech, officials of the two vaccine makers said on Tuesday.

India's COVID-19 vaccination drive was launched by Prime Minister Narendra Modi on January 16.

Serum Institute has received another order from the government for 10 million doses of Covishield, a company official said in response to a query.

The government had earlier placed a purchase order with Serum Institute of India (SII) for 1.1 crore doses of AstraZeneca-Oxford COVID-19 vaccine, Covishield.

When asked, a Bharat Biotech spokesperson said, "The company has received a letter of comfort from the Government of India to supply another 4.5 million (or 45 lakh) doses''.

The spokesperson also added that Bharat Biotech will also be exporting its COVID-19 vaccine, Covaxin, to Brazil and the United Arab Emirates.

The company is also likely to export the vaccine to the Philippines and other South Asian countries, the spokesperson said.

The government had earlier placed an order for 55 lakh doses of Covaxin from Bharat Biotech.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus VaccineCoronavirus Tests

First Published: Feb 09 2021 | 6:58 PM IST

Next Story